Does ATORVASTATIN Cause Product packaging quantity issue? 8 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Product packaging quantity issue have been filed in association with ATORVASTATIN (Atorvastatin calcium). This represents 0.0% of all adverse event reports for ATORVASTATIN.
8
Reports of Product packaging quantity issue with ATORVASTATIN
0.0%
of all ATORVASTATIN reports
0
Deaths
1
Hospitalizations
How Dangerous Is Product packaging quantity issue From ATORVASTATIN?
Of the 8 reports, 1 (12.5%) required hospitalization.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ATORVASTATIN. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does ATORVASTATIN Cause?
Type 2 diabetes mellitus (7,556)
Myalgia (7,155)
Drug hypersensitivity (3,929)
Drug ineffective (3,865)
Fatigue (3,439)
Arthralgia (3,338)
Rhabdomyolysis (3,286)
Dyspnoea (3,137)
Nausea (2,888)
Asthenia (2,791)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which ATORVASTATIN Alternatives Have Lower Product packaging quantity issue Risk?
ATORVASTATIN vs ATORVASTATIN\EZETIMIBE
ATORVASTATIN vs ATOSIBAN
ATORVASTATIN vs ATOVAQUONE
ATORVASTATIN vs ATOVAQUONE\PROGUANIL
ATORVASTATIN vs ATRACURIUM